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No gender survival difference in a population 
of patients with chronic heart failure related 
to left ventricular systolic dysfunction 
and receiving optimal medical therapy
Absence de différence de survie liée au sexe dans une population de patients
en insuffisance cardiaque chronique secondaire à une dysfonction systolique 
ventriculaire gauche et sous traitement médical optimal
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Summary
Introduction.— Controversial results have been published concerning a possible gender survival
difference in patients with chronic heart failure (CHF).
Methods.— We analysed data from consecutive patients with stable CHF admitted to our
department for prognostic evaluation. Patients underwent coronary angiography, echo-
cardiography, radionuclide angiography and a cardiopulmonary exercise test. 
Results.— We included 613 consecutive patients of whom 115 (19%) were women. The major
difference in clinical characteristics was a higher proportion of ischaemic cardiomyopathy in
men compared to women (51% vs 28%, p<0.0001) and a lower left ventricular ejection fraction
(35±9 vs 38±9%, p=0.001). Therapeutic management was similar in men and women. A total of
140 cardiovascular-related deaths and 4 urgent transplantations occurred during a median
follow-up of 1.234 days. There was no gender difference in cardiac survival. Cardiovascular
mortality rates at 2 years were 11% in men and 13% in women.
Conclusions.— Despite a lower percentage of ischaemic cardiopathy in women, no gender
survival benefit was found in our population of CHF patients receiving optimal medical therapy.
© 2008 Published by Elsevier Masson SAS.
Résumé 
Introduction. — La notion d’une survie différente en fonction du sexe chez des patients porteurs
d’une insuffisance cardiaque chronique (ICC) est controversée.
Méthodes. — Nous avons suivi tous nos patients consécutifs avec une ICC stable admis dans notre
service pour un bilan pronostique, comprenant une coronarographie, une échocardiographie,
une détermination isotopique des fractions d’éjection et une épreuve d’effort métabolique.
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Résultats. — Nous avons inclus dans l’analyse 613 patients dont 115 de sexe féminin (19 %). Les
différences cliniques significatives en fonction du sexe sont, chez l’homme par rapport à la
femme, une proportion plus importante de cardiopathie ischémique (51 % vs 28 %, p < 0,0001)
et une fraction d’éjection du ventricule gauche plus basse (35 ± 9 % vs 38 ± 9 %, p = 0,001). Le
traitement des patients est identique quel que soit le sexe. Pendant un suivi de 1 234 jours, il
y a eu 140 décès d’origine cardio-vasculaire et 4 transplantations en urgence. La survie est
identique quel que soit le sexe. La mortalité cardiovasculaire à 2 ans est de 11 % chez les
hommes et de 13 % chez les femmes.
Conclusion. — Dans notre population de patients suivis pour une ICC stable et recevant un
traitement médical optimal, malgré une proportion plus faible de cardiopathie ischémique chez
la femme, la survie cardiovasculaire est identique quel que soit le sexe.
© 2008 Published by Elsevier Masson SAS.
Introduction
Previous studies have shown gender differences in clinical
characteristics, therapeutic management and survival in
patients with cardiac diseases. Although some specific
aspects of metabolism could explain theses differences,
gender difference in survival in patients with chronic heart
failure (CHF) remains controversial. Some studies clearly
demonstrate better survival in women with CHF, particu-
larly in post-hoc analyses of large mortality trials [1-3].
However, other studies have failed to demonstrate a gen-
der survival benefit [4-6]. In the SOLVD (Studies Of Left
Ventricular Dysfunction) registry and the DIG (Digitalis
Investigation Group) trial, women had a greater mortality
than men [7, 8]. These controversial results could be rela-
ted to selection bias in mortality trials and gender differen-
ces in the management of CHF.
The aim of the present study was to compare gender dif-
ferences in clinical characteristics, therapeutic manage-
ment and survival in a large cohort of patients with CHF
related to left ventricular systolic dysfunction from a ter-
tiary hospital, who was receiving contemporary treatment
including high doses of renin inhibitors and beta-blockers. 
Methods
All patients referred to our department for non-invasive eva-
luation of left ventricular systolic dysfunction were conside-
red for inclusion in the study. Before inclusion, treatment of
the patients was optimized with the introduction and/or up-
titration to maximal tolerated doses of renin inhibitors and/
or beta-blockers. The non-invasive evaluation was performed
3 months after maximal tolerated doses of both renin inhibi-
tors and beta-blockers were reached. During this treatment
optimization, patients had systematic coronary angiography
to help define the aetiology of left ventricular systolic dys-
function. Patients were included in the study if they were
ambulatory, stable for at least 2 months and had an echocar-
diographic left ventricular ejection fraction (LVEF) ≤45%.
Patients were excluded if they had an acute coronary syn-
drome or had undergone coronary revascularization or car-
diac surgery in the previous 3 months. 
All of the patients underwent echocardiography, radio-
nuclide angiography, and a cardiopulmonary exercise test
as described previously [9]. Blood samples were drawn in
the morning with the patient in the supine position for stan-
dard measurements and brain natriuretic peptide (BNP)
determination. BNP samples were immediately put on ice,
centrifuged at 4°C within 20 minutes and the supernatant
was immediately stored at -70°C until assayed. Plasma BNP
concentrations were measured by radio-immunoassay
(Shionoria BNP kit, Shionogi & Co. Ltd., Osaka, Japan). Nor-
mal values were <21.1 pg/mL with inter-assay and intra-
assay coefficients of variation of 4.2% and 2.7%, respecti-
vely, for the concentration of 21.1 pg/mL, and 2.1% and 2%,
respectively, for the concentration of 520 pg/mL.
Definitions
Patients with ischaemic cardiomyopathy were defined as
those with a proven history of myocardial infarction (signifi-
cant Q waves on the electrocardiogram and/or significant
increase in creatinine kinase levels during a previous hospi-
talization) and/or stenosis >50% in one of the major coro-
nary arteries. Patients who did not fulfil these criteria were
considered to have non-ischaemic cardiomyopathy. If coro-
nary angiography was not performed or if the patient did not
have a proven history of myocardial infarction, they were
considered as having undetermined cardiomyopathy (7 men
and 3 women), except for young patients (<30 years’ old)
without any risk factor for atherosclerosis. These patients
were considered to have non-ischaemic cardiomyopathy.
Qualitative classification of doses of angiotensin-conver-
ting enzyme (ACE) inhibitor was defined using the recom-
mendations of the European Society of Cardiology. High
doses were defined as the highest recommended doses,
intermediate as the lowest recommended doses, and low as
non-recommended doses of ACE inhibitor [10]. 
Statistics
Results are expressed as mean±SD except for BNP values,
which are presented as median with interquartile range.
Discrete variables were compared using χ2 analysis or with
Fisher’s exact test, when indicated. Continuous variables
were compared by the unpaired Student's t test or by the
non-parametric Mann-Whitney test. Follow-up was perfor-
med either by direct examination or by contact with the
general practitioner. Cardiac mortality was defined as car-
diac-related death or urgent cardiac transplantation (United
Network for Organ Sharing [UNOS] status 1); patients who
had non-urgent transplantation (UNOS status 2) were censo-
red at the time of transplantation. A cardiac event was defi-
ned as cardiac-related death or cardiac transplantation
(UNOS1 and 2). A Kaplan-Meier method was performed to
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estimate the cumulative survival. Differences in survival
were compared with a log-rank test. A P value ≤0.05 was
considered statistically significant. Statistics were perfor-
med with the SPSS software version 15.01 (Chicago, Illinois).
Results
Clinical characteristics and treatment
The present analysis is based on 613 patients with stable
CHF, of whom 115 were women (19%). Major clinical cha-
racteristics of the study population are summarized in
Table 1. Women were less likely to have ischaemic cardio-
myopathy than men (28% vs 51%, p<0.0001). LVEF and right
ventricular ejection fraction were significantly higher in
women compared to men. Other differences were related
to differences in weight and height between men and
women.
Treatment according to gender is summarized in table 2.
Prescription rates of different CHF drugs were similar in
men and women with the exception of statins, more fre-
quently given to men, and carvedilol, more frequently
given to women. Doses of carvedilol were significantly
higher in men, with the difference being explained partly
by their higher weight. In patients weighing <85 kg, doses of
Table 1 Gender differences in major characteristics of the study population.
Men
(n=498)
Women
(n=115)
P
Age, years 56±12 55±14 NS
Weight, kg 81±16 70±20 <0.0001
Height, cm 172±9 162±7 <0.0001
Body surface area, m2 1.94±0.2 1.74±0.21 <0.0001
NYHA III, n (%) 89 (18%) 19 (16%) NS
Atrial fibrillation, n (%) 65 (13%) 8 (7%) NS
Diabetes mellitus, n (%) 131 (26%) 22 (19%) NS
History of hypertension, n (%) 190 (38%) 49 (43%) NS
Ischaemic cardiomyopathy, n (%)* 248 (51%) 31 (28%) <0.0001
Heart rate at rest, bpm 67±13 68±15 NS
Systolic blood pressure at rest, mmHg 118±19 116±17 NS
QRS duration, ms 117±34 117±44 NS
Complete LBBB,% 100 (20%) 26 (23%) NS
Left ventricular ejection fraction,% 35±9 38±9 0.001 
Right ventricular ejection fraction,% 41±12 45±13 0.001
Left atrial diameter, mm 44±8.7 39.2±8.3 <0.0001
Left atrial diameter/m2 22.9±4.5 22.9±5.3 NS
LVEDD, mm 63.5±10.4 60.4±9.1 0.003
LVEDD/m2 33±5.7 35.4±6.4 <0.0001
E/A ratio 1.48±1.4 1.33±1.14 NS
Mitral deceleration time, ms 192±76.6 199±87.8 NS
Peak VO2, mL/min/kg 16.1±5.4 14.7±4.3 0.004
% maximal predicted VO2 60±16.7 70.9±19.1 <0.0001
Sodium, mEq/L 138±3.1 139±3.2 0.03
Creatinine, mg/L 11.7±5.4 10±5.3 0.003
Creatinine clearance, ml/min 54.5±18.2 51.6±20.5 NS
Uric acid, mg/L 78.8±21.6 67.8±21.9 <0.0001
Haemoglobin, g/dL 13.9±2.4 12.7±1.7 <0.0001
BNP, pmol/L 38 [3-99] 24 [1.5-87] NS
BNP, B-type natriuretic peptide; LBBB, left bundle branch block; LVEDD, left ventricular end-diastolic 
diameter; NYHA, New York Heart Association; VO2, oxygen consumption.
* exclusion of the 10 patients who did not have coronary angiography 
Gender and CHF 245
carvedilol remained higher in men than women, but the dif-
ference was not significant (43±18 vs 36±15 mg/d, p=0.08).
Survival analysis
A total of 140 cardiovascular-related deaths and 29 non-
cardiac related deaths occurred over a median follow-up of
1.234 days; four patients had an urgent transplantation and
27 a non-urgent transplantation (table 3). One patient was
lost to follow-up. Survival was similar in women and men.
Cardiovascular mortality rates at 1 year were 6% in men and
7% in women. At 2 years, these rates were 11% and 13%, res-
pectively. Figure 1 shows survival curves according to gen-
der. Figure 2 shows survival curves in ischaemic and non-
ischaemic patients according to gender. Similar results
were obtained when the analysis included all cardiovascular
events (cardiovascular-related deaths and all transplanta-
tions) as the major end-points (data not shown).
Discussion
The results of the present study demonstrate no gender sur-
vival difference in our population of patients with CHF rela-
ted to left ventricular systolic dysfunction, despite modest
differences in clinical characteristics. Women were less
Table 2 Treatment of the study population according to gender.
Men
(n=498)
Women
(n=115)
P
ACE inhibitor, n (%) 460 (92%) 104 (90%) NS
% at maximal recommended doses
% at mimimal recommended doses
314 (68%)
73 (16%)
66 (63%)
16 (15%)
NS
NS
ARB, n (%) 35 (7%) 9 (8%) NS
ACE inhibitor or ARB, n (%) 484 (97%) 111 (97%) NS
Bisoprolol, n (%) 328 (66%) 63 (55%) NS
Doses of bisoproplol, mg/d 8.4±3.8 8.3±3.0 NS
Carvedilol, n (%) 102 (20%) 35 (30%) 0.02
Doses of carvedilol, mg/d 52.5±27 40±18 0.01
Diuretic, n (%) 369 (74%) 80 (70%) NS
Spironolactone, n (%) 139 (28%) 29 (25%) NS
Digoxin, n (%) 150 (30%) 35 (30%) NS
Amiodarone, n (%) 76 (15%) 19 (17%) NS
Aspirin, n (%) 223 (45%) 48 (42%) NS
Oral anticoagulant, n (%) 177 (36%) 41 (36%) NS
Statin, n (%) 236 (47%) 37 (32%) 0.005
Allopurinol, n (%) 53 (11%) 6 (5%) NS
Implantable cardiodefibrillator, n (%) 65 (13%) 10 (9%) NS
Resynchronization therapy, n (%) 19 (4%) 5 (4%) NS
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
Table 3 Major clinical events during follow-up.
Men
(n=498)
Women
(n=115)
P
Cardiovascular death, n (%) 111 (22%) 29 (25%) NS
Urgent transplantation, n 3 1 NS
Non-urgent transplantation, n (%) 24 (5%) 3 (3%) NS
Non-cardiovascular death, n (%) 26 (5%) 3 (3%) NS
Figure 1. Survival curves of the whole population according to
gender. Survival rates at 1 and 2 years are reported (top for men
and bottom for women).
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likely to have ischaemic cardiomyopathy and had higher
LVEF and right ventricular ejection fraction. We have also
shown that our therapeutic management was similar irres-
pective of gender, and that survival was similar in men and
in women. 
Gender-related clinical characteristics
As expected, and as reported in previous studies, the major
gender difference in clinical characteristics was the lower
proportion of ischaemic cardiomyopathy in women compa-
red with men [3, 11]. This significant difference was highli-
ghted by the fact that in the present study, coronary angio-
graphy was performed systematically. Thus, we are sure of
the coronary status of most of our patients, with the excep-
tion of 10 who did not have an angiography. As in previous
studies [11, 12], we found modest but significant differen-
ces in LVEF and right ventricular ejection fraction between
men and women. Other differences in clinical characteris-
tics in our study population were related to differences in
body surface area. Left ventricular end diastolic and left
atrial diameters were slightly higher in men compared to
women, as was serum creatinine concentration. However,
these differences were not significant after adjustment for
body surface area. Moreover, adjusted left ventricular end
diastolic diameter was significantly greater in women com-
pared with men. As expected, peak VO2 was higher in men,
even after adjustment for predicted values. Previous stu-
dies clearly demonstrated that peak VO2 is related to mus-
cle mass, which is higher in men. Predicted values of VO2
have been determined in large cohorts of male subjects but
have to be interpreted with caution in women and in ove-
rweight or underweight patients [13]. Previous studies have
shown other significant gender differences: women are
often older than men, with a higher proportion of diabetic
women, in atrial fibrillation, and with a history of hyper-
tension [2, 14-16]. All of these differences in previous stu-
dies could be explained by selection bias [3, 11] but also by
the inclusion of CHF patients with or without depressed
LVEF [14, 16]. In our population, all consecutive CHF
patients with left ventricular systolic dysfunction were
included and, except for ischaemic cardiomyopathy,
women and men had a similar clinical presentation, parti-
cularly the same mean age. Of interest, BNP levels – a
powerful prognostic parameter – were similar in men and
women [17, 18]. Moreover, while studies have shown that
women undergo fewer invasive procedures such as coronary
angiography [16], this was not the case in the present
study.
Gender differences in therapeutic
management
Most previous large mortality trials have demonstrated the
same efficacy of CHF drugs in men and women, including
ACE inhibitors, angiotensin receptor blockers, beta-bloc-
kers and aldosterone antagonists [2, 19]. One exception is
digoxin, which in a post-hoc analysis from the DIG trial
showed a greater mortality rate in women receiving
digoxin versus men [8]. Despite the lack of a gender diffe-
rence in therapeutic efficacy, previous studies have
demonstrated under-treatment of women versus men [3,
20, 21], even in acute heart failure [12]. In the present
study, women had the same rate of coronary angiography
and the same therapeutic management, except for a minor
difference concerning carvedilol, which was more often
given to women. Recent studies also suggest that women
are less likely to receive implantable cardioverter-defi-
brillators for primary and secondary prevention of sudden
cardiac death [22, 23]. This difference in therapeutic
management and in clinical characteristics could explain
the controversial results concerning the gender impact on
survival in CHF.
Gender impact on survival
This gender impact on survival in CHF is controversial, with
some studies demonstrating a survival benefit in women [1-
3, 11, 16, 24-27], others showing no benefit [21, 28] and a
Figure 2. Survival curves according to aetiology of the cardiomyopathy and gender. A. Ischaemic cardiomyopathy; and B. non-ischaemic
cardiomyopathy. Survival rates at 1 and 2 years are reported in each subgroup (top for men and bottom for women).
A B
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few reporting a worse prognosis [7, 8], especially after
myocardial infarction [29]. As for clinical characteristics,
these controversial results could be explained by selection
bias or the inclusion of CHF patients with preserved LVEF.
Studies from tertiary hospital, as ours, with the selection of
CHF patients, could explain the previous controversial
results. Moreover, some studies were conducted several
years ago, before the modern treatment era [26, 27]. Diffe-
rences in therapeutic management could also explain the
gender survival difference in previous studies [20]. In some
reports, the benefit appears restricted to subgroups such as
non-ischaemic patients [11, 24] and non-diabetic patients
[30]. A post-hoc analysis of the BEST (Beta-blocker Evalua-
tion of Survival Trial) trial found no gender survival diffe-
rence in patients with ischaemic cardiomyopathy, but a
significantly better survival in women with non-ischaemic
cardiomyopathy [11].
Several studies have suggested pathophysiological gen-
der-related differences that could explain the survival
benefit in women. For example, the remodelling process
during arterial hypertension is different in men and women,
with a major impact of diabetes mellitus [31, 32]. Heart
rate variability also differs [33], which could explain the
discrepancy in incidence of sudden cardiac death.
Study limitations 
Although we included all consecutive patients, the present
study was not prospective. As in many previous cardiovas-
cular studies, the number of women was limited, particu-
larly those with ischaemic cardiomyopathy. Because of the
limited number of patients, we did not perform multiva-
riate analyses. We enrolled selected patients in a tertiary
hospital so our results cannot be extended to the whole
CHF population, especially to older patients or those with
preserved left ventricular systolic function. There were
few significant gender differences in clinical characteris-
tics, suggesting a lack of selection bias in our study popu-
lation. CHF treatment was similar in men and women, with
similar doses prescribed, but information regarding treat-
ment modification during the follow-up period was not
collected. These changes may influence the outcome of
our patients. However, therapeutic optimization, with
maximal tolerated doses of ACE inhibitors and beta-bloc-
kers, was performed in all of our patients before they were
enrolled. We have shown in a previous study with the same
inclusion criteria that limited changes in CHF treatment
and doses occur during follow-up [34]. Finally, we do not
have any information on re-hospitalization rates during
the follow-up period and on the quality of life of our
patients. Our study was focused on hard end-points, such
as total mortality, cardiovascular mortality and cardiac
transplantation.
Conclusions
We demonstrate no gender survival difference in this large
population of patients from a tertiary hospital with stable
CHF related to left ventricular systolic dysfunction recei-
ving high doses of renin inhibitors and beta-blockers.
Although fewer women had ischaemic cardiomyopathy, this
result could be partly explained by similar therapeutic
management in men and women.
No author has any conflict of interest.
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